Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + fulvestrant in HR+/HER2- advanced breast cancer
NCT03927456Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Jun 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing SHR6390 + Fulvestrant with Placebo + Fulvestrant (2 arms). Primary endpoint: Investigator-assessed Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03927456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927456.